Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

MDT US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Medtronic Public Limited Company(MDT US)

$102.12+1.131.12%(Market Open · 14:44:25 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

MDT US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Medtronic Public Limited Company(MDT US)

$102.12+1.131.12%(Market Open · 14:44:25 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Medtronic Public Limited Company — Company Profile

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Geoffrey Straub Martha
Headquarters
Galway, L2, IE
IPO Date
May 2, 1973
Employees
95,000
Website
www.medtronic.com

Key Metrics

Price
$86.38
Market Cap
$110.57B
Revenue (TTM)
$36.36B
Net Income (TTM)
$4.80B
EPS (TTM)

Medtronic Public Limited Company — Company Profile

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Geoffrey Straub Martha
Headquarters
Galway, L2, IE
IPO Date
May 2, 1973
Employees
95,000
Website
www.medtronic.com

Key Metrics

Price
$86.38
Market Cap
$110.57B
Revenue (TTM)
$36.36B
Net Income (TTM)
$4.80B
EPS (TTM)
3.75
P/E (TTM)
21.14
P/B (TTM)
0.00
Dividend Yield
3.26%
ROE (TTM)
2.33%
ROA (TTM)
1.25%
Operating Margin
19.66%
Beta
0.18

Dividends

Last Dividend
$0.71
Last Yield
0.03%

Summary

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Website
www.medtronic.com
Location
Galway, L2, IE
Phone353 1 438 1700
Employees95,000
CEOGeoffrey Straub Martha
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMay 2, 1973

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.3K)

Expand
  • SC 13GMedtronic plc10 Nov
  • Form 4Marinaro Michael4 Nov
  • Form 4Lofton Kevin E21 Oct
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)21 Oct
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)21 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers19 Oct
  • Form 4Marinaro Michael16 Oct
  • Form 4Martha Geoffrey16 Oct
  • SC 13G/AMiniMed Group, Inc.16 Oct
  • Form 4Medtronic plc16 Oct
  • Form 144Marinaro Michael15 Oct
  • Form 144Martha Geoffrey15 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)14 Oct
  • Form 425Business combination communication14 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)13 Oct
  • Form 425Business combination communication13 Oct
  • Form 425Business combination communication9 Oct
  • Form 425Business combination communication8 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)8 Oct
  • Form 425Business combination communication8 Oct

EDINET Filings(53)

Expand
  • IRExtraordinary Report20 Oct
  • IRExtraordinary Report20 Oct
  • IRExtraordinary Report8 Sep
  • IRExtraordinary Report8 Sep
  • 10-KAnnual Securities Report (2025.04.26-2026.04.24)20 Aug
  • IRExtraordinary Report20 Aug
  • IRExtraordinary Report20 Aug
  • IRExtraordinary Report19 Apr
  • IRExtraordinary Report19 Apr
  • IRExtraordinary Report13 Mar
  • IRExtraordinary Report23 Jan
  • IRExtraordinary Report23 Jan
  • IRSemi-Annual Report (2025.04.26-2025.10.24)21 Jan
  • IRExtraordinary Report9 Dec 2025
  • IRExtraordinary Report19 Oct 2025
  • IRExtraordinary Report19 Oct 2025
  • IRExtraordinary Report8 Sep 2025
  • IRExtraordinary Report8 Sep 2025
  • 10-KAmended Annual Securities Report26 Aug 2025
  • 10-KAnnual Securities Report (2024.04.27-2025.04.25)25 Aug 2025

News

  • 4 Healthcare Dividend Stocks for Retirees. One Yields Over 4%03:47PM
  • 14 dividend stocks selected for long-term growth11:01AM
  • Medtronic Kept Growing When All Eyes Were On AI, Time To Give This Growth Justice12 Nov
  • 3 Legacy Health Care Dividend Stocks That Never Go Out of Style11 Nov
  • 4 Dividend Stocks That Can Thrive Under a Democratic Congress11 Nov
  • Medtronic (MDT) Dips More Than Broader Market: What You Should Know10 Nov
  • 12,505 Medtronic PLC $MDT Shares Purchased by Alps Advisors Inc.10 Nov
  • 3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market6 Nov
  • 2 Growth Stocks to Buy in November Without Any Hesitation5 Nov
  • Medtronic to announce financial results for its second quarter of fiscal year 20274 Nov
  • These 12 stocks are good bets to beat the 10-year Treasury over the next decade4 Nov
  • TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study3 Nov
  • Medtronic PLC $MDT Stock: Heritage Investors Management Corp Reduces Stake3 Nov
  • Hennessy Advisors Inc. Sells 31,426 Shares of Medtronic PLC $MDT3 Nov
  • Medtronic (MDT) Ascends While Market Falls: Some Facts to Note2 Nov
  • The Best Dividend Stocks to Buy With $5,000 in November2 Nov
  • Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?1 Nov
  • Why the Market Dipped But Medtronic (MDT) Gained Today29 Oct
  • Orchestra BioMed Announces Virtue SAB Presentation at TCT 202629 Oct
  • American Century Equity Income Fund Q3 2026 Portfolio Activity29 Oct

Mentions in Filings

  • … hn*** is a senior healthcare executive with more than 25 years of experience building and leading medical technology, diagnostics and pharmaceutical businesses across Europe, the Middle East, Africa and Central Asia. At <strong>Medtronic</strong>, he was Business Head of the Spinal and Biologics Division, with P&L responsibility above $100 million across Eastern Europe, the Middle East, Central Asia and Africa. As Managing Director of Amico for Levant and North A …
    Sunshine Biopharma Inc.Medtronic Public Limited Company·DEF 14A - DEFINITIVE PROXY STATEMENT·Q4 26·12 Nov
  • … Coronary Syndrome (ACS) in high-risk patients. The initiative is co-funded by the European Union’s Innovative Health Initiative and led by University Medical Center Groningen and Royal Philips. HeartBeam joins Philips, <strong>Medtronic</strong>, GE HealthCare and other global healthcare leaders. HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies. HEART-CHECK is a hybrid effectiveness-implementation study that will evaluate the HeartBeam …
    HeartBeam, Inc.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … the Eastern District of Louisiana, the United States District Court for the Western District of Texas, the United States District Court for the Western District of Michigan, the Circuit Court of the State of Oregon and the United States District Court for the Southern District of New York. The Company refers to all of the aforementioned litigation, or claim notices, collectively as the “VBM Litigation.” ​ *Resolution of <strong>Medtronic</strong> Litigation* ​
    ELUTIA INC.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … led with the SEC and declared effective on January 8, 2026, and a prospectus supplement dated January 20, 2026. ● On January 20, 2026, the Company entered into a stock purchase agreement with Covidien Group S.à r.l. (“<strong>Medtronic</strong>”), a wholly owned subsidiary of Medtronic plc, pursuant to which the Company issued and sold to Medtronic 15,652,173 shares of Common Stock at a purchase price of $5.75 per share (the “Medtronic Private Placement”). The …
    Anteris Technologies Global Corp.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … business entity’s expenses and address requests from investors for more detailed information about the types 11 Table of Contents of expenses in commonly presented expense captions. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2024-03 on its condensed consolidated financial statements. 3. <strong>Medtronic</strong> Agreement
    Orchestra BioMed Holdings, Inc.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … , Regulatory Compliance & Quality Assurance, Bard Access Systems, Inc. January 1997: Vice President, Corporate Regulatory Affairs, CR Bard, Inc. December 2000: Vice President, Regulatory, Clinical, and Quality Division, <strong>Medtronic</strong> Xomed, Inc. September 2003: Vice President, Corporate Regulatory and Clinical Division, CR Bard, Inc. June 2007: Vice President, Quality, Regulatory, Clinical, and Medical Affairs, Medtronic Sofamor Danek USA, Inc. Septe …
    OLYMPUS CORPORATIONMedtronic Public Limited Company·Interim Report - Semi-Annual Report (2026.04.01-2027.03.31)·10 Nov·10 Nov

Key Stats

Trading

Px/Chg 1D$86.38 / -0.07%
Avg Volume9.56M
Beta0.18
Mkt Cap110.57B
FD Mkt Cap116.17B

Float

Shrs Out/Float1.28B / 1.28B
Short Float0.01%
Days to Cover1.73
Stock Repurchased$1.03B

Current Valuation

EV108.78B
EV/EBITDA11.51
EV/Sales2.90
P/B0.00
P/S2.95
FCF Yield1.17%
ROE2.33%
ROA1.25%
Current Ratio2.54

Dividend

Cash$0.71
Yield3.26%
Yield (TTM)3.26%

Estimates

P/E21.14
Est P/E0.00
Est EPS1.54
Est PEG0.00

Valuation

Metric5Yr AvgAug '23Aug '24Aug '25Aug '26Oct '26
PRICE-BASED RATIOS
Price / Earnings68.3229.1332.27111.6693.3575.22
Price / Sales8.713.513.6713.2211.8311.33
Price / Book Value1.862.132.362.462.370.00
Price / Free Cash Flow49.0223.9022.8157.0455.6585.71
ENTERPRISE VALUE METRICS
Enterprise Value134,304.7132,458.8142,562.7144,552.9143,171.5108,777.7
Enterprise Value / Sales10.124.244.4016.1914.6011.15
Enterprise Value / EBITDA41.2215.2317.3863.5454.2955.64
Enterprise Value / EBIT55.0522.0825.66100.7371.1655.64

Financials

Full Financials
Millions USD5Yr CAGR (%)Apr '22Apr '23Apr '24Apr '25Apr '26
INCOME STATEMENT
Revenue3.5%31,686.031,227.032,364.033,537.036,364.0
Gross Income2.4%21,541.020,508.021,148.021,905.023,643.0
EBITDA2.8%8,777.08,697.08,203.09,218.09,809.0
EBIT3.1%6,070.06,000.05,556.06,357.06,851.0
Net Income-1.2%5,039.03,758.03,676.04,662.04,800.0
EPS (Diluted)0%3.732.822.763.613.73
BALANCE SHEET
Cash & ST Inv-5.4%10,573.07,959.08,005.08,965.0—
Total Assets25.5%90,981.090,948.089,981.091,680.0—
Total Liabilities4.3%38,259.039,283.039,561.043,424.0—
Total Shareholder Equity-3%52,551.051,483.050,214.048,024.0—
CASH FLOW
Net Operating Cash Flow-5.4%7,346.06,039.06,787.07,044.07,330.0
Cap Ex8.6%-1,368.0-1,459.0-1,587.0-1,859.0-1,904.0
Free Cash Flow-2.4%5,978.04,580.05,200.05,185.05,426.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)102.88
Basic Shares1,280.05
Market Cap131,685.1
Diluted Shares1,285.10
Fully Diluted Shares Outstanding1,285.10
Fully Diluted Market Cap132,204.7
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,793.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value129,892.1

Segment data

Revenue

by Products and services

  • Cardiac And Vascular Group39%
  • Neuroscience Group28%
  • Medical Surgical24%
  • Diabetes Group9%

Revenue

by Geography

  • United States80%
  • Total Other Countries, Excluding United States And Ireland20%
  • Ireland0%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US

3.75
P/E (TTM)
21.14
P/B (TTM)
0.00
Dividend Yield
3.26%
ROE (TTM)
2.33%
ROA (TTM)
1.25%
Operating Margin
19.66%
Beta
0.18

Dividends

Last Dividend
$0.71
Last Yield
0.03%

Summary

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Website
www.medtronic.com
Location
Galway, L2, IE
Phone353 1 438 1700
Employees95,000
CEOGeoffrey Straub Martha
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMay 2, 1973

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.3K)

Expand
  • SC 13GMedtronic plc10 Nov
  • Form 4Marinaro Michael4 Nov
  • Form 4Lofton Kevin E21 Oct
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)21 Oct
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)21 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers19 Oct
  • Form 4Marinaro Michael16 Oct
  • Form 4Martha Geoffrey16 Oct
  • SC 13G/AMiniMed Group, Inc.16 Oct
  • Form 4Medtronic plc16 Oct
  • Form 144Marinaro Michael15 Oct
  • Form 144Martha Geoffrey15 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)14 Oct
  • Form 425Business combination communication14 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)13 Oct
  • Form 425Business combination communication13 Oct
  • Form 425Business combination communication9 Oct
  • Form 425Business combination communication8 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)8 Oct
  • Form 425Business combination communication8 Oct

EDINET Filings(53)

Expand
  • IRExtraordinary Report20 Oct
  • IRExtraordinary Report20 Oct
  • IRExtraordinary Report8 Sep
  • IRExtraordinary Report8 Sep
  • 10-KAnnual Securities Report (2025.04.26-2026.04.24)20 Aug
  • IRExtraordinary Report20 Aug
  • IRExtraordinary Report20 Aug
  • IRExtraordinary Report19 Apr
  • IRExtraordinary Report19 Apr
  • IRExtraordinary Report13 Mar
  • IRExtraordinary Report23 Jan
  • IRExtraordinary Report23 Jan
  • IRSemi-Annual Report (2025.04.26-2025.10.24)21 Jan
  • IRExtraordinary Report9 Dec 2025
  • IRExtraordinary Report19 Oct 2025
  • IRExtraordinary Report19 Oct 2025
  • IRExtraordinary Report8 Sep 2025
  • IRExtraordinary Report8 Sep 2025
  • 10-KAmended Annual Securities Report26 Aug 2025
  • 10-KAnnual Securities Report (2024.04.27-2025.04.25)25 Aug 2025

News

  • 4 Healthcare Dividend Stocks for Retirees. One Yields Over 4%03:47PM
  • 14 dividend stocks selected for long-term growth11:01AM
  • Medtronic Kept Growing When All Eyes Were On AI, Time To Give This Growth Justice12 Nov
  • 3 Legacy Health Care Dividend Stocks That Never Go Out of Style11 Nov
  • 4 Dividend Stocks That Can Thrive Under a Democratic Congress11 Nov
  • Medtronic (MDT) Dips More Than Broader Market: What You Should Know10 Nov
  • 12,505 Medtronic PLC $MDT Shares Purchased by Alps Advisors Inc.10 Nov
  • 3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market6 Nov
  • 2 Growth Stocks to Buy in November Without Any Hesitation5 Nov
  • Medtronic to announce financial results for its second quarter of fiscal year 20274 Nov
  • These 12 stocks are good bets to beat the 10-year Treasury over the next decade4 Nov
  • TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study3 Nov
  • Medtronic PLC $MDT Stock: Heritage Investors Management Corp Reduces Stake3 Nov
  • Hennessy Advisors Inc. Sells 31,426 Shares of Medtronic PLC $MDT3 Nov
  • Medtronic (MDT) Ascends While Market Falls: Some Facts to Note2 Nov
  • The Best Dividend Stocks to Buy With $5,000 in November2 Nov
  • Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?1 Nov
  • Why the Market Dipped But Medtronic (MDT) Gained Today29 Oct
  • Orchestra BioMed Announces Virtue SAB Presentation at TCT 202629 Oct
  • American Century Equity Income Fund Q3 2026 Portfolio Activity29 Oct

Mentions in Filings

  • … hn*** is a senior healthcare executive with more than 25 years of experience building and leading medical technology, diagnostics and pharmaceutical businesses across Europe, the Middle East, Africa and Central Asia. At <strong>Medtronic</strong>, he was Business Head of the Spinal and Biologics Division, with P&L responsibility above $100 million across Eastern Europe, the Middle East, Central Asia and Africa. As Managing Director of Amico for Levant and North A …
    Sunshine Biopharma Inc.Medtronic Public Limited Company·DEF 14A - DEFINITIVE PROXY STATEMENT·Q4 26·12 Nov
  • … Coronary Syndrome (ACS) in high-risk patients. The initiative is co-funded by the European Union’s Innovative Health Initiative and led by University Medical Center Groningen and Royal Philips. HeartBeam joins Philips, <strong>Medtronic</strong>, GE HealthCare and other global healthcare leaders. HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies. HEART-CHECK is a hybrid effectiveness-implementation study that will evaluate the HeartBeam …
    HeartBeam, Inc.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … the Eastern District of Louisiana, the United States District Court for the Western District of Texas, the United States District Court for the Western District of Michigan, the Circuit Court of the State of Oregon and the United States District Court for the Southern District of New York. The Company refers to all of the aforementioned litigation, or claim notices, collectively as the “VBM Litigation.” ​ *Resolution of <strong>Medtronic</strong> Litigation* ​
    ELUTIA INC.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … led with the SEC and declared effective on January 8, 2026, and a prospectus supplement dated January 20, 2026. ● On January 20, 2026, the Company entered into a stock purchase agreement with Covidien Group S.à r.l. (“<strong>Medtronic</strong>”), a wholly owned subsidiary of Medtronic plc, pursuant to which the Company issued and sold to Medtronic 15,652,173 shares of Common Stock at a purchase price of $5.75 per share (the “Medtronic Private Placement”). The …
    Anteris Technologies Global Corp.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … business entity’s expenses and address requests from investors for more detailed information about the types 11 Table of Contents of expenses in commonly presented expense captions. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2024-03 on its condensed consolidated financial statements. 3. <strong>Medtronic</strong> Agreement
    Orchestra BioMed Holdings, Inc.Medtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … , Regulatory Compliance & Quality Assurance, Bard Access Systems, Inc. January 1997: Vice President, Corporate Regulatory Affairs, CR Bard, Inc. December 2000: Vice President, Regulatory, Clinical, and Quality Division, <strong>Medtronic</strong> Xomed, Inc. September 2003: Vice President, Corporate Regulatory and Clinical Division, CR Bard, Inc. June 2007: Vice President, Quality, Regulatory, Clinical, and Medical Affairs, Medtronic Sofamor Danek USA, Inc. Septe …
    OLYMPUS CORPORATIONMedtronic Public Limited Company·Interim Report - Semi-Annual Report (2026.04.01-2027.03.31)·10 Nov·10 Nov

Key Stats

Trading

Px/Chg 1D$86.38 / -0.07%
Avg Volume9.56M
Beta0.18
Mkt Cap110.57B
FD Mkt Cap116.17B

Float

Shrs Out/Float1.28B / 1.28B
Short Float0.01%
Days to Cover1.73
Stock Repurchased$1.03B

Current Valuation

EV108.78B
EV/EBITDA11.51
EV/Sales2.90
P/B0.00
P/S2.95
FCF Yield1.17%
ROE2.33%
ROA1.25%
Current Ratio2.54

Dividend

Cash$0.71
Yield3.26%
Yield (TTM)3.26%

Estimates

P/E21.14
Est P/E0.00
Est EPS1.54
Est PEG0.00

Valuation

Metric5Yr AvgAug '23Aug '24Aug '25Aug '26Oct '26
PRICE-BASED RATIOS
Price / Earnings68.3229.1332.27111.6693.3575.22
Price / Sales8.713.513.6713.2211.8311.33
Price / Book Value1.862.132.362.462.370.00
Price / Free Cash Flow49.0223.9022.8157.0455.6585.71
ENTERPRISE VALUE METRICS
Enterprise Value134,304.7132,458.8142,562.7144,552.9143,171.5108,777.7
Enterprise Value / Sales10.124.244.4016.1914.6011.15
Enterprise Value / EBITDA41.2215.2317.3863.5454.2955.64
Enterprise Value / EBIT55.0522.0825.66100.7371.1655.64

Financials

Full Financials
Millions USD5Yr CAGR (%)Apr '22Apr '23Apr '24Apr '25Apr '26
INCOME STATEMENT
Revenue3.5%31,686.031,227.032,364.033,537.036,364.0
Gross Income2.4%21,541.020,508.021,148.021,905.023,643.0
EBITDA2.8%8,777.08,697.08,203.09,218.09,809.0
EBIT3.1%6,070.06,000.05,556.06,357.06,851.0
Net Income-1.2%5,039.03,758.03,676.04,662.04,800.0
EPS (Diluted)0%3.732.822.763.613.73
BALANCE SHEET
Cash & ST Inv-5.4%10,573.07,959.08,005.08,965.0—
Total Assets25.5%90,981.090,948.089,981.091,680.0—
Total Liabilities4.3%38,259.039,283.039,561.043,424.0—
Total Shareholder Equity-3%52,551.051,483.050,214.048,024.0—
CASH FLOW
Net Operating Cash Flow-5.4%7,346.06,039.06,787.07,044.07,330.0
Cap Ex8.6%-1,368.0-1,459.0-1,587.0-1,859.0-1,904.0
Free Cash Flow-2.4%5,978.04,580.05,200.05,185.05,426.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)102.88
Basic Shares1,280.05
Market Cap131,685.1
Diluted Shares1,285.10
Fully Diluted Shares Outstanding1,285.10
Fully Diluted Market Cap132,204.7
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,793.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value129,892.1

Segment data

Revenue

by Products and services

  • Cardiac And Vascular Group39%
  • Neuroscience Group28%
  • Medical Surgical24%
  • Diabetes Group9%

Revenue

by Geography

  • United States80%
  • Total Other Countries, Excluding United States And Ireland20%
  • Ireland0%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US